ONTX vs. INDP, VINC, RNXT, TXMD, ADXN, LSTA, APM, BIVI, MEIP, and SYBX
Should you be buying Onconova Therapeutics stock or one of its competitors? The main competitors of Onconova Therapeutics include Indaptus Therapeutics (INDP), Vincerx Pharma (VINC), RenovoRx (RNXT), TherapeuticsMD (TXMD), Addex Therapeutics (ADXN), Lisata Therapeutics (LSTA), Aptorum Group (APM), BioVie (BIVI), MEI Pharma (MEIP), and Synlogic (SYBX). These companies are all part of the "pharmaceutical preparations" industry.
Onconova Therapeutics (NASDAQ:ONTX) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
In the previous week, Indaptus Therapeutics had 1 more articles in the media than Onconova Therapeutics. MarketBeat recorded 1 mentions for Indaptus Therapeutics and 0 mentions for Onconova Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.00 beat Onconova Therapeutics' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.
8.0% of Onconova Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 3.3% of Onconova Therapeutics shares are owned by insiders. Comparatively, 27.1% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Indaptus Therapeutics has a net margin of 0.00% compared to Onconova Therapeutics' net margin of -8,930.97%. Indaptus Therapeutics' return on equity of -91.78% beat Onconova Therapeutics' return on equity.
Onconova Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of ∞. Indaptus Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 491.13%. Given Onconova Therapeutics' higher probable upside, research analysts clearly believe Onconova Therapeutics is more favorable than Indaptus Therapeutics.
Indaptus Therapeutics has lower revenue, but higher earnings than Onconova Therapeutics. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.
Onconova Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
Onconova Therapeutics received 372 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Indaptus Therapeutics an outperform vote while only 59.59% of users gave Onconova Therapeutics an outperform vote.
Summary
Onconova Therapeutics beats Indaptus Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Onconova Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Onconova Therapeutics Competitors List
Related Companies and Tools
